Deep Track group reports 5.17% stake in Shattuck Labs (STTK) via warrants

Rhea-AI Filing Summary

Shattuck Labs ownership filing: Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin report beneficial ownership of 5,000,033 shares of Common Stock, representing 5.17% of the class as reported in the cover data. The calculation uses 96,801,464 shares (based on 95,508,165 outstanding as of June 11, 2026 plus 1,293,299 Pre‑Funded Warrants). The Pre‑Funded Warrants are exercisable subject to a 9.99% ownership limitation.

Insights

Corporate Governance Analyst

Schedules 13G show passive/beneficial ownership above 5%.

Deep Track entities and David Kroin are disclosed as beneficial owners of 5,000,033 shares, or 5.17%, using the filing's stated denominator of 96,801,464 shares. The filing attributes shared voting and dispositive power for that amount.

The filing also states inclusion of 1,293,299 Pre‑Funded Warrants that are exercisable subject to a 9.99% Maximum Percentage, and notes the issuer will not effect exercises that would exceed that cap. Subsequent filings would show any change in holdings.

Securities Structuring Specialist

Pre‑Funded Warrants drive the computation and the ownership cap matters.

The ownership percentage is computed using an aggregate of common shares and Pre‑Funded Warrants (96,801,464), per the excerpt. The warrants are exercisable into common stock but limited by a 9.99% cap that the issuer enforces.

Cash‑flow treatment and any planned exercises are not described here; filings or amendments would be needed to disclose changes to the registered position or exercise activity.

Key Figures

Shares beneficially owned: 5,000,033 shares Percent of class: 5.17% Denominator used: 96,801,464 shares +3 more

6 metrics

Shares beneficially owned 5,000,033 shares ownership reported as of June 17, 2026

Percent of class 5.17% calculated using 96,801,464 shares

Denominator used 96,801,464 shares 95,508,165 outstanding as of June 11, 2026 plus 1,293,299 Pre‑Funded Warrants

Common shares outstanding (as stated) 95,508,165 shares outstanding as of June 11, 2026 per issuer prospectus

Pre‑Funded Warrants included 1,293,299 warrants exercisable to common shares subject to cap

Maximum Percentage cap 9.99% exercise limitation on Pre‑Funded Warrants

Key Terms

Pre‑Funded Warrants, Beneficially owned, Shared dispositive power

3 terms

Pre‑Funded Warrants financial

"The beneficially owned shares include 1,293,299 Pre‑Funded Warrants exercisable to common shares"

Pre-funded warrants are a type of security that lets an investor buy a company’s common shares later by paying almost the full price up front; the tiny remaining exercise amount is paid when the warrant is converted into a share. Think of it like prepaying for a gift card that you can redeem for a stock: the issuer gets cash now and the investor can convert later. They matter to investors because conversion increases the number of outstanding shares (dilution) and can be used to manage ownership thresholds and regulatory or timing constraints.

Beneficially owned regulatory

"Amount beneficially owned: 5,000,033 (b) Percent of class: 5.17%"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared dispositive power regulatory

"Shared Dispositive Power 5,000,033.00"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/17/2026 - 04:01 PM Accepted by SEC EDGAR 06/17/2026 - 04:00 PM Learn about SEC filing dates

FAQ

What stake does Deep Track report in Shattuck Labs (STTK)?

Deep Track reports beneficial ownership of 5,000,033 shares, equal to 5.17% of the class. This figure is calculated using 96,801,464 shares, per the filing's stated denominator.

How did the filing compute the 5.17% ownership for STTK?

The percentage uses a base of 96,801,464 shares, derived from 95,508,165 common shares outstanding as of June 11, 2026 plus 1,293,299 Pre‑Funded Warrants included in the calculation.

Are Pre‑Funded Warrants included in Deep Track's reported holdings?

Yes. The filing includes 1,293,299 Pre‑Funded Warrants exercisable into common stock and counts them toward the beneficial ownership calculation under the stated mechanics.

Is there a limit on exercising the Pre‑Funded Warrants reported in STTK?

The Pre‑Funded Warrants are subject to a 9.99% Maximum Percentage; the issuer will not effect exercise that would cause the holder to exceed 9.99% of outstanding common stock after exercise.

Who filed the Schedule 13G for Shattuck Labs and who signed it?

The filing is joint by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. The signatures show David Kroin signing in his roles on June 17, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Shattuck Labs, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

82024L103

(CUSIP Number)

06/10/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 82024L103

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,000,033.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,000,033.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,000,033.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.17 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 82024L103

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,000,033.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,000,033.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,000,033.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.17 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 82024L103

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,000,033.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,000,033.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,000,033.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.17 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Shattuck Labs, Inc.
(b)	Address of issuer's principal executive offices: 500 W. 5th Street, Suite 1200, Austin, TX 78701
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 82024L103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,000,033
(b)	Percent of class: 5.17%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 5,000,033
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 5,000,033
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	06/17/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	06/17/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	06/17/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of June 17, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 96,801,464 shares, calculated using 95,508,165 Common Stock outstanding as of June 11, 2026, according to the issuer's Prospectus filed with the SEC on June 11, 2026 and 1,293,299 Pre-Funded Warrants that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 1,293,299 Pre-Funded Warrants exercisable to common shares, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Pre-Funded Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: June 17, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin